Oxigene to focus on CA4P for macular degeneration

By Lisa Kerner

Charlotte, N.C., Sept. 12 - Oxigene, Inc., as part of its plan to focus its ophthalmology strategy on oral or other non-intravitreal forms of administrations of Combretastatin A4 Phosphate (CA4P), completed enrollment of a phase 2 CA4P clinical trial in myopic macular degeneration (MMD-213).

The masked, multi-center trial will evaluate the safety and efficacy of three dose groups (27 mg/m2, 36 mg/m2, and 45 mg/m2) of CA4P for the treatment of subfoveal choroidal neovascularization (CNV) in 36 subjects with pathologic myopia.

Results from this trial are expected to in the first quarter of 2007.

Oxigene is an emerging pharmaceutical company based in Waltham, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.